UOBAM Ping An ChiNext ETF

SGX: CXS

1.388

+4.28%

Share Price in SGD. As of 11 May 11:00:16 SGT

All

Chart

Fund Highlights

Fund Description

UOBAM Ping An ChiNext ETF seeks to track the performance of the ChiNext Index by investing into the Ping An ChiNext ETF, providing access to the 100 largest companies on China's innovation-focused ChiNext Market.

Key Features

  • 1
    Exposure to China's ChiNext Market innovation companies
    This fund tracks the ChiNext Index, which is made up of the 100 largest companies listed on China's ChiNext Market, a segment focused on technology, healthcare, and other high-growth industries. The fund invests primarily in Industrials, Information Technology, and Healthcare, which together account for over 70% of the portfolio.
  • 2
    Feeder fund structure via Ping An
    Rather than holding each company's shares directly, this ETF invests substantially all of its assets into the Ping An ChiNext ETF, which in turn holds the underlying ChiNext A-shares. This feeder fund structure gives Singapore investors a convenient and regulated way to gain exposure to China's innovation sector without needing a mainland China brokerage account.
  • 3
    Dual currency trading on SGX with no dividend distributions
    The ETF is listed on SGX in Singapore dollars (CXS) and US dollars (CXU), so you can buy and sell through a regular brokerage account in either currency. The fund does not distribute dividends, and any income from the underlying holdings is retained within the fund rather than paid out to investors.
Fund Allocation

As of 31 Mar 2026

SymbolWeight
Contemporary Amperex Technology Co Ltd19.72
Zhongji Innolight Co Ltd9.31
Eoptolink Technology Inc Ltd7.54
East Money Information Co Ltd4.65
Sungrow Power Supply Co Ltd4.27
Victory Giant Technology Huizhou Co Ltd2.93
Suzhou TFC Optical Communication Co Ltd2.54
Shenzhen Inovance Technology Co Ltd2.53
Shenzhen Mindray Bio-Medical Electronics Co Ltd1.92
Wens Foodstuff Group Co Ltd1.76
Beansprout Analysis
News
Fund Documents
chatbubble
Discussion

0 comments